Royce & Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Royce & Associates’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-20,000	Closed	-$1.47M	–	1202
2019 Q1	$1.47M	Sell	20,000 -11,100	-36%	-$755K	0.01%	809
2018 Q4	$1.32M	Hold	31,100	–	–	0.01%	813
2018 Q3	$1.47M	Sell	31,100 -20,000	-39%	-$1.11M	0.01%	872
2018 Q2	$2.52M	Sell	51,100 -10,000	-16%	-$378K	0.02%	776
2018 Q1	$1.88M	Sell	61,100 -60,000	-50%	-$1.67M	0.01%	866
2017 Q4	$2.21M	Sell	121,100 -130,000	-52%	-$2.02M	0.01%	823
2017 Q3	$2.94M	Hold	251,100	–	–	0.02%	731
2017 Q2	$917K	Buy	251,100 +118,063	+89%	+$452K	0.01%	985
2017 Q1	$692K	Buy	+133,037	New	+$729K	﹤0.01%	1020

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Royce & Associates's MRTX Position: Q2 2019 in Review

Royce & Associates sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2019, closing a stake of 20,000 shares — an estimated $1.47M sold.

Royce & Associates first reported a position in MRTX in Q1 2017 and held it in 9 quarters. The position peaked at $2.94M in Q3 2017. 172 funds tracked by Wall St. Rank hold MRTX as of Q2 2019.

Royce & Associates reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Royce & Associates sold 20,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.47M.
Royce & Associates first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2017 and held it in 9 quarters.
Royce & Associates's Mirati Therapeutics, Inc. Common Stock position peaked at $2.94M in Q3 2017.
172 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Royce & Associates's 13F filing for Q2 2019, filed 12 Aug 2019.